hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status

Gemcitabine is still one of the standard chemotherapy regimens for pancreatic ductal adenocarcinoma (PDAC). Gemcitabine uptake into tumor cells is mainly through the human equilibrative nucleoside transport 1 (hENT1). It was therefore proposed as a potential predictive biomarker of gemcitabine effic...

Full description

Bibliographic Details
Main Authors: Jerome Raffenne, Remy Nicolle, Francesco Puleo, Delphine Le Corre, Camille Boyez, Raphael Marechal, Jean François Emile, Peter Demetter, Armelle Bardier, Pierre Laurent-Puig, Louis de Mestier, Valerie Paradis, Anne Couvelard, Jean Luc VanLathem, John R. MacKey, Jean-Baptiste Bachet, Magali Svrcek, Jerome Cros
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Cancers
Subjects:
pancreatic adenocarcinoma
hent1
gemcitabine
Online Access:https://www.mdpi.com/2072-6694/11/11/1808

Internet

https://www.mdpi.com/2072-6694/11/11/1808

Similar Items